Abstract
We describe our local experience in the management of haemophilia B patients with factor IX Fc fusion protein. Two children with haemophilia B were managed with the use of a personalised/tailored dosing schedule of factor IX Fc fusion protein. Compared with the standard half-life factor IX, prophylaxis with factor IX Fc fusion protein was cost-effective, with much less injections, better bleeding control, improved tolerability or no inhibitor development.
Reference8 articles.
1. National Hemophila Foundation . Bleeding disorder, types of bleeding disorder (hemophilia B), 2019. Available: https://www.hemophilia.org/Bleeding-Disorders/Types-of-Bleeding-Disorders/Hemophilia-B
2. Guidelines for the management of hemophilia
3. Hemophilia therapy: the future has begun
4. A new era for hemophilia B treatment
5. Extended half-life factor VIII and factor IX preparations;Graf;Transfus Med Hemother,2018